Search peptides, terms, sources/
Research source · 2023

Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
Adults with obesity, without diabetes
Sample size
338
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 August 2026

Limitations

Sponsor-funded (Eli Lilly); phase 2, not yet independently replicated in a peer-reviewed phase 3 publication.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.